Bloomberg are among many experts that predict the global medical cannabis market could be worth more than US$130 billion by 2029. Following suit of the global medical cannabis market, the Australian medicinal cannabis market is beginning to take flight.
At Australian Natural Therapeutics Group, we are uniquely positioned to supply the domestic and European markets with Australian grown, Australian made, pharmaceutical grade medicinal cannabis products.
We are the first and only Australian medicinal cannabis company to receive Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA) and Good Agricultural and Collection Practices (GACP) verification for medicinal cannabis flower manufacturing. These certify our products meet the highest pharmaceutical standards worldwide and open up further opportunities for export into the European Union. We are on track to be the first Australian medicinal cannabis company to export cannabis flower to the EU for commercial purposes since export was legalised in 2018.
We are motivated by the possibilities that medicinal cannabis offers in assisting the management of various health conditions. And we understand that no two patients are alike, that’s why we are committed to developing premium, proprietary medicinal cannabis strains whose unique plant profiles offer therapeutic benefit and effect. Our proprietary strains support our clinical research trials into the use of cannabinoid therapies to prevent, treat and ease disease.
What sets ANTG apart is our focus on quality, expertise and investment in research and development. We adhere to strict specialist standards and quality checks at every step of the cultivation, extraction and production process to ensure optimal quality and maximum medicinal benefit, with upgraded innovative cultivation facilities exceeding Australian standards. Our research partners include the University of Newcastle and the National Institute for Complementary Medicines at Western Sydney University amongst many others – together we progress to further strengthen the position of medicinal cannabis, including our proprietary strains, through continuous research and development.
“Research and development is at the core of this company, and we see it as our responsibility to provide robust evidence to healthcare professionals and the public. The body of evidence is extraordinary and it’s growing every single day.” – Matt Cantelo, Founder and CEO of ANTG.
Here at ANTG our overarching goal is to develop evidential and technological capabilities to instantly identify the right strain and dose of medical cannabis for general wellbeing, to treat specific health conditions, and develop preventive therapies. Our team is united in their ambition to change lives through medical cannabis. Join us on our journey.
Register your interest in becoming an investor in medicinal cannabis here.
For more on the latest industry trends, legislation and scientific research in exciting new field, take a look at our news section.
ANTG has listed two new THC-dominant medicinal cannabis strains on the Australian Register of Therapeutic Goods (ARTG).
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.